| 29/06 | 89bio Prices Upsized $94.5 Million Public Offering |  |
| 29/06 | 89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock,.. | |
| 28/06 | 89bio Launches $75 Million Offering of Shares, Warrants; Sees Positive Results for Phas.. | |
| 28/06 | 89BIO: Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Pa.. | |
| 28/06 | 89BIO, INC.: Other Events (form 8-K) | |
| 28/06 | 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded.. | |
| 28/06 | 89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in P.. | |
| 28/06 | 89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermi.. | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2500 Value Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Dynamic Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Value Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell Small Cap Comp Value Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2500 Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000E Value Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 2000 Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000E Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000 Value Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell 3000 Index | |
| 24/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from Russell Small Cap Completeness Index | |
| 21/06 | 89bio to Present Additional Pegozafermin Data at EASL International Liver Congress&trad.. | |
| 20/06 | 89BIO, INC.(NASDAQGM: ETNB) dropped from S&P Global BMI Index | |
| 07/06 | 89BIO, INC.: Submission of Matters to a Vote of Security Holders (form 8-K) | |
| 12/05 | 89BIO, INC. Management's Discussion and Analysis of Financial Condition and Results
of.. | |
| 11/05 | 89BIO, INC.: Results of Operations and Financial Condition (form 8-K) | |
| 11/05 | 89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 11/05 | 89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update | |
| 11/05 | 89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update | |
| 03/05 | 89bio to Participate in Upcoming Investor Conferences | |
| 26/04 | 89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG) | |
| 25/03 | SECTOR UPDATE: Health Care Stock Edging Higher Near Friday Close | |
| 25/03 | SECTOR UPDATE: Health Care Stocks Weakening in Afternoon Trading | |
| 24/03 | 89BIO, INC. Management's Discussion and Analysis of Financial Condition and Results
of.. | |
| 24/03 | 89bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | |
| 24/03 | 89BIO: Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate.. | |
| 24/03 | 89BIO, INC.: Results of Operations and Financial Condition (form 8-K) | |
| 24/03 | 89bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | |
| 24/03 | 89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporat.. | |
| 14/03 | Spruce Biosciences Names New Chief Medical Officer | |
| 04/03 | 89BIO: Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors - Fo.. | |
| 04/03 | 89BIO, INC. Change in Directors or Principal Officers (form 8-K/A) | |
| 24/02 | 89BIO: Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors - Fo.. | |
| 24/02 | 89BIO, INC.: Change in Directors or Principal Officers (form 8-K) | |
| 24/02 | 89bio, Inc. Appoints Edward Morrow Atkinson to the Board | |
| 24/02 | 89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors | |
| 09/02 | 89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Confer.. | |
| 24/01 | 89BIO: Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial.. | |
| 24/01 | 89BIO, INC.: Other Events (form 8-K) | |
| 24/01 | 89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Tria.. | |
| 24/01 | 89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 2.. | |
| 2021 | 89BIO, INC.(NASDAQGM: ETNB) added to NASDAQ Biotechnology Index | |
| 2021 | 89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Vo.. | |
| 2021 | 89bio, Inc. Presents New Data from Phase 1B/2A Nash Study Showing Bio89-100 Reduces Spl.. | |
| 2021 | 89BIO, INC. Management's Discussion and Analysis of Financial Condition and Results
of.. | |
| 2021 | 89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Form.. | |
| 2021 | 89BIO, INC.: Results of Operations and Financial Condition (form 8-K) | |
| 2021 | 89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update | |
| 2021 | 89bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem.. | |
| 2021 | 89bio Announces Appointment of Kathy LaPorte to its Board of Directors - Form 8-K | |
| 2021 | 89BIO, INC.: Change in Directors or Principal Officers, Financial Statements and Exhibits.. | |
| 2021 | 89bio Announces Appointment of Kathy LaPorte to its Board of Directors | |
| 2021 | 89bio Announces Appointment of Kathy Laporte to Its Board of Directors | |
| 2021 | 89BIO: to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD's Th.. | |
| 2021 | INSIDER SELL: 89bio | |
| 2021 | 89BIO: to Participate in the Cantor Global Healthcare Conference | |
| 2021 | INSIDER SELL: 89bio | |
| 2021 | 89BIO, INC.(NASDAQGM: ETNB) added to S&P Global BMI Index | |
| 2021 | 89bio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference | |
| 2021 | 89BIO: Management's Discussion and Analysis of Financial Condition and Results of Operati.. | |
| 2021 | 89BIO: Reports Second Quarter 2021 Financial Results and Provides Corporate Update (Form .. | |
| 2021 | 89BIO, INC.: Results of Operations and Financial Condition (form 8-K) | |
| 2021 | 89Bio, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and.. | |
| 2021 | 89BIO: Reports Second Quarter 2021 Financial Results and Provides Corporate Update | |
| 2021 | 89BIO: to Participate in Upcoming Investor Conferences | |
| 2021 | 89BIO: Completes Target Enrollment in Histology Cohort to Evaluate Fatty Liver Disease Tr.. | |
| 2021 | 89BIO: Completed Target Enrollment in Histology Cohort to Evaluate BIO89-100 for the Trea.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Espańol
Franēais (France)
Nederlands (Nederland)
Nederlands (Belgiė)
Rapporto
